Juvelook

What it is

Juvelook is a sterile lyophilized powder reconstituted before injection. Each vial contains 42.5 mg of poly(D,L-lactic acid) (PDLLA) microspheres plus 7.5 mg of non-crosslinked hyaluronic acid. It is positioned as a dermal-level skin booster for early-to-moderate photoaging, pore refinement, and skin texture improvement. Lenisna is the higher-concentration sister product from the same manufacturer, containing 170 mg of PDLLA plus 30 mg of non-crosslinked HA per vial. Lenisna is administered at deeper subcutaneous or periosteal levels for deeper wrinkles, significant skin laxity, and volume loss.

The PDLLA microspheres feature a patented reticular structure designed to maximize surface area for collagen induction while minimizing nodule formation. This geometry is the key differentiation from earlier PLLA-based products such as Sculptra, whose crystalline fragments are sharper and require post-treatment massage. PDLLA differs from PLLA in its amorphous structure of randomized D- and L-monomers, producing more uniform hydrolytic degradation, a lower glass transition temperature, and fewer sharp crystalline fragments.

VAIM Co., Ltd. (바임), the Seoul-based manufacturer founded in 2014, reported 2024 revenue of 66.5 billion KRW with an operating margin near 80 percent, exporting to 72 countries. In January 2026, Korean trade press reported VAIM was exploring a potential sale of the company, reflecting market interest in the Juvelook franchise.

How it works

Once injected into the dermis, PDLLA microspheres act as a biodegradable biostimulatory scaffold. Macrophages phagocytose the microspheres and polarize toward the M2 anti-inflammatory phenotype via NRF2 phosphorylation. This elevates IL-10 and reduces NF-kB activation and matrix metalloproteinase expression in fibroblasts. M2 macrophage-conditioned media in turn reduces senescence markers in adipose-derived stem cells and increases their proliferation. Activated stem cells secrete TGF-beta and FGF2, driving collagen synthesis and extracellular matrix remodeling. In vivo, PDLLA injection has been shown to increase expression of NRF2, IL-10, collagen types 1a1 and 3a1, and to enhance stem cell proliferation.

The immediate plumping effect comes from the HA carrier, which provides transient volumization while the PDLLA phase initiates fibroblast activation over four to twelve weeks. PDLLA hydrolysis produces lactic acid, which is further metabolized to carbon dioxide and water, leaving no permanent residue. The degradation timeline is six to twenty-four months depending on formulation concentration.

A 2023 clinical study by Seo and colleagues in 20 participants using Juvelook reported significant improvements in skin elasticity, firmness, hydration, and wrinkle depth with no serious adverse events.

Origin and development

VAIM Co., Ltd. was founded in 2014 in Seoul, focusing on tissue-regeneration products built on biocompatible biodegradable polymer technology. VAIM developed and patented the PDLLA manufacturing process that produces porous, reticular microspheres, and launched Juvelook commercially in the Korean market in 2019 following MFDS certification. Lenisna was developed as a higher-concentration sister product using the same PDLLA-HA hybrid chemistry. Both products hold MFDS certification and CE mark in the EU.

VAIM presented Juvelook and Lenisna at KOREADERMA 2024 with sessions on wrinkle reduction and volume restoration. Babitalk's 2025 spring/summer trend report placed 쥬베룩 as a top-tier elasticity keyword alongside 울쎄라 and 인모드, confirming its mainstream status in the Korean cosmetic market.

Regulatory status

Because Juvelook is classified in Korea as a medical device rather than a pharmaceutical, its regulatory pathway is distinct from drug approvals.

Typical protocol

Based on Korean clinic practice and published guidance:

• Juvelook: 2 to 3 sessions at 4 to 6 week intervals for the initial course. Results typically last 6 to 12 months. Maintenance every 12 to 18 months. Standard dosing is one full vial of 2.0 to 2.5 mL reconstituted volume per full-face session.
• Lenisna: 2 to 3 sessions at 6 to 8 week intervals. Results typically last 18 to 24 months.
• Anesthesia: topical numbing cream applied 20 to 30 minutes prior to injection.
• Session duration: 20 to 30 minutes.
• Downtime: mild redness and swelling for 1 to 2 days at injection sites.
• Post-care: avoid pressure on treated areas for the first day, apply daily sun protection, and resume normal activity. No post-treatment massage is required, in contrast to Sculptra. The round porous shape of the PDLLA particles is the cited reason.

Variants

Juvelook and Lenisna are not interchangeable. The choice depends on the indication, anatomical area, and treatment depth.

Commonly reported effects

Published clinical evidence for PDLLA biostimulators includes the following. The cited studies are representative, not exhaustive.

• Dual-phase improvement. Immediate HA hydration is visible within 24 to 48 hours, with progressive collagen buildup peaking eight to twelve weeks after the final session. Reduced pore size, improved texture, and reduced wrinkle depth are confirmed in published clinical work.
• Nodule risk profile. Korean dermatologists using Juvelook combined with microneedle radiofrequency reported zero nodules over a two-year observation period, attributed to Juvelook's porous round particle design contrasted with the sharper crystalline fragments from older PLLA products.
• Vascular occlusion. PDLLA dermal-filler literature documents rare but serious vascular events. Wang and colleagues reported a case of branch retinal artery occlusion in a 35-year-old woman after PDLLA filler. Tan and colleagues reported a case series of 10 patients with multifocal strokes and vision loss after PDLLA filler. Vascular occlusion is a known risk for any dermal-filler injection and is technique-dependent.
• Other documented adverse events. Granuloma formation from delayed hypersensitivity and filler migration from improper technique appear in the broader PDLLA literature.

The body of evidence for Juvelook specifically is supportive, but as with most newer injectables it draws from small trials and observational cohorts. Larger randomized controlled trials are still being called for in academic reviews.

Korea vs US availability

Juvelook is widely available in Korea across general dermatology clinics, specialized aesthetic clinics, and plastic surgery hospitals. Per 모두닥 (Modoodoc) 2026 platform data, Juvelook pricing ranges from approximately ₩49,500 per 1 cc at promotional or event pricing to ₩770,000 per session at premium Cheongdam clinics. A typical 8 cc vial session listed on 여신티켓 (Yeoshin Ticket) is approximately ₩319,000 at event pricing.

In the United States, Juvelook and Lenisna are not cleared for cosmetic skin booster use. Where the products appear, practitioner wholesale pricing is approximately $152 to $220 per vial. Direct US-vs-Korea retail price comparison is not clean because US clinic use of these products falls outside cleared cosmetic indications.

International clients seek Juvelook in Korea because of its non-availability in the US and EU for cosmetic injection, lower local pricing, and Korean dermatologists' procedural experience with the specific product.

What to research before

Before booking Juvelook or any PDLLA-based skin booster in Korea:

• Verify the clinic is licensed and the injector is a qualified physician. Our credential verification guide covers KSPRS and specialty registries.
• Confirm which product is being used and why. Juvelook and Lenisna are not interchangeable. Ask for the specific product name and the rationale for that choice based on your treatment area.
• Be cautious of "FDA-approved" marketing. Neither Juvelook nor Lenisna is FDA-cleared for cosmetic injection. Clinics that claim otherwise are conflating PDLLA's general FDA material clearance with specific product approval.
• Check product authenticity at the appointment. Ask to see the original packaging.
• Understand the timeline. Visible collagen-driven improvement does not appear immediately. The HA carrier provides early hydration; the structural change unfolds over weeks.
• See also: our Korean Surgery Safety Guide and red flags guide.

Related procedures

• Rejuran — Korean polynucleotide skin booster with a different mechanism
• Skin boosters — umbrella category for hydration and regenerative injectables
• Sculptra — older PLLA biostimulator, US-cleared
• HA fillers — volumizing fillers for structural contouring rather than collagen stimulation

Sources

1. Lee KWA et al. Poly-d,l-lactic Acid (PDLLA) Application in Dermatology: A Literature Review. Polymers (Basel) 2024;16(18):2583. https://pmc.ncbi.nlm.nih.gov/articles/PMC11434839/
2. Rho NK, Han KH, Cho M, Kim HS. Injectable Skin Boosters in Aging Skin Rejuvenation. Archives of Plastic Surgery 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11560330/
3. Dr Rachel Ho MD. Juvelook Skincare: Could PDLLA be the next big K-beauty trend? https://www.drrachelho.com/blog/juvelook-skincare-topical-pdlla-korea/
4. Pulse by 매일경제 (Maeil Kyungjae). Medical device maker VAIM to be up for grabs. January 2026. https://pulse.mk.co.kr/news/english/11947014
5. QD Skin Clinic (Gangnam). Juvelook Dosage & Protocol in Korea. https://www.gangnamskincenter.com/blog/juvelook-dosage-protocol-in-korea
6. VAIM Global / KOREADERMA 2024 feature. https://www.youtube.com/watch?v=lUEAkWN4F04
7. 위키트리/바비톡 (Wikitree/Babitalk), 2025 S/S trend report. https://www.wikitree.co.kr/articles/1037057
8. Dr Prlja Medical (Belgrade). Juvelook and Lenisna Treatment. https://drprljamedical.com/en/juvelook-and-lenisna-treatment/
9. 모두닥 (Modoodoc), 쥬베룩 가격정보 2026. https://www.modoodoc.com/blog/price-detail
10. FillerOutlet.com. Juvelook Volume 200mg / Lenisna (wholesale practitioner pricing). https://filleroutlet.com/products/juvelook-volume-200mg-lenisna/